Patent · US Active

RNAi modulation of HIF-1 and therapeutic uses thereof

US7737265B2 · kind B2 · utility

111Cited by

8References

27Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Akin Akinc · Cambridge, US
Antonin de Fougerolles · Waterloo, BE
Hans-Peter Vornlocher · Bayreuth, DE
Philipp Hadwiger · Kulmbach, DE
Birgit Bramlage · Ebikon, CH

Key dates

Filing date	Jun 27, 2006
Grant date	Jun 15, 2010
Priority date	—
Expiry date	Oct 15, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/322
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1α, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.